A new study reports that blood tests used to identify Alzheimer’s disease may also help forecast who among cognitively healthy older adults is at higher risk of developing symptoms later. The research focuses on whether biomarkers detectable in blood can flag future Alzheimer’s progression before clinical signs appear. Sources describe the test as useful not only for diagnosis, but also for risk stratification in people who currently do not show Alzheimer’s symptoms. The findings indicate that some individuals with elevated blood-based markers are more likely to develop Alzheimer’s-related cognitive or clinical changes over time. While the reports emphasize the potential for earlier identification, they do not claim immediate clinical replacement for existing diagnostic pathways. Instead, the study frames the approach as a step toward earlier detection and improved targeting of monitoring and preventive interventions. Overall, the outlets agree that the evidence supports the feasibility of using blood biomarkers to identify healthy people who may benefit from closer follow-up as risk increases.